Company: NCEL
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001213900-25-025839
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 6-K
Chunk 3
---
3 Million Equity Financing and $25 Million
Equity Facility Agreement.” A copy of this press release is furnished herewith as Exhibit 99.5.

Safe Harbor Statement

This
Report of Foreign Private Issuer on Form 6-K contains expressed or implied forward-looking statements pursuant to U.S. Federal securities
laws, including statements related to the timing and completion of the Offering and the Purchase Agreement, the satisfaction of customary
closing conditions related to the Offering and the intended use of proceeds therefrom and the satisfaction of customary closing conditions
related to the Purchase Agreement. For example, the Company is using forward-looking statements when discussing the subsequent closing
of the Offering. These forward-looking statements and their implications are based on the current expectations of the management of NLS
only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading “Risk Factors”
in NLS’ annual report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission, or SEC,
which is available on the SEC’s website, www.sec.gov, and in subsequent filings made by NLS with the SEC.

This
Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-284696, 333-284811,
333-282788, 333-262489, 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>2

EXHIBIT INDEX</div>

| Exhibit No. 
 99.1        |     | Document Description                                                                                                                            
 Form of Securities Purchase Agreement, dated March 27, 2025, by and between NLS Pharmaceutics and the certain purchasers thereto.               |
|:------------|:----|:------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.2        |     | Form of Registration Rights Agreement                                                                                                           |
| 99.3        |     | Common Shares Purchase